Annual Report Details Apyx Medical's $52.8M Revenue, $(0.27) EPS for 2025
Summary
Apyx Medical reported its full fiscal year 2025 results in its 10-K filing, detailing $52.8 million in revenue and a loss per share of $(0.27). This follows an earlier 8-K filing today which reported strong Q4 2025 results and beat analyst EPS estimates, and a generic 10-K timeline entry. This news provides the specific full-year figures, showing the company achieved 9.9% year-over-year revenue growth and significantly narrowed its net loss from $(23.6) million to $(11.1) million. This improvement was driven by its Surgical Aesthetics business and cost reductions, indicating improving financial health and operational efficiency. Investors will monitor continued growth in Surgical Aesthetics, the impact of new product launches like AYON, and further progress on profitability.
At the time of this announcement, APYX was trading at $3.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.8M. The 52-week trading range was $0.76 to $4.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.